Trials / Terminated
TerminatedNCT05648006
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
A Prospective, Multicenter, Open, Randomized Controlled Phase II Clinical Study Evaluating Recombinant Oncolytic HSV2（OH2）Therapeutic Injecta(Vero Cell) for Human Use(rHSV2hGM-CSF) in Combination With Capecitabine for First-line Maintenance Therapy in Advanced Colorectal Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Binhui Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 17 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multicenter, open, randomized controlled Phase II clinical study to evaluate the efficacy and safety of intratumoral injection of OH2 combined with capecitabine for first-line maintenance of advanced colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | OH2 | Oncolytic Type 2 Herpes Simplex Virus |
| DRUG | Capecitabine | 1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks |
| DRUG | Bevacizumab | Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks. |
Timeline
- Start date
- 2023-10-17
- Primary completion
- 2024-04-15
- Completion
- 2024-04-15
- First posted
- 2022-12-13
- Last updated
- 2024-04-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05648006. Inclusion in this directory is not an endorsement.